ArticleTranslational lung cancer research2025
Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between elevated multiple circulating biomarkers and short-term mortality in critically ill lung cancer patients: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating tumor DNA (ctDNA) has recently garnered attention as a promising prognostic biomarker in cancer patients. This review aimed to evaluate the prognostic significance of ctDNA in patients with non-small cell lung cancer (NSCLC) at different treatment timepoints. Methods: A comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, Scopus, ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP) was performed covering the period from January 2016 to May 2022, with updates monitored until June 2024. Studies reporting ctDNA positivity versus negativity and associated survival outcomes were included. Hazard ratios (HRs) or risk ratios (RRs) were pooled using random-effects models for relapse-free survival (RFS), overall survival (OS), and recurrence risk. The risk of bias of observational studies was assessed by the Newcastle-Ottawa Scale (NOS). Results: Fifty-two studies were included. Total sample sizes of these studies ranged from 12 to 330 participants. Baseline ctDNA positivity was associated with worse RFS [HR =2.23, 95% confidence interval (CI): 1.82-2.75] in all NSCLCs. Among resectable NSCLC, postoperative ctDNA was strongly associated with inferior RFS (HR =5.64, 95% CI: 3.88-8.19) and OS (HR =4.17, 95% CI: 2.22-7.84). Similar trends were noted after full-course treatment for both resectable and unresectable patients. CtDNA detection often preceded radiographic or clinical recurrence, supporting its potential as an early indicator of relapse. Conclusions: CtDNA positivity serves as a robust prognostic marker of worse survival and higher recurrence in NSCLC patients throughout the treatment cycle. Early ctDNA detection may facilitate timely therapeutic interventions and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.